Brennan MJ. The effect of opioid therapy on endocrine function. Am J Med. 2013;126(3 Suppl 1):S12-8. doi: 10.1016/j.amjmed.2012.12.001.
2. Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol. 2007;17(6-7):377-93. doi: 10.1016/j.euroneuro.2006.10.006.
3. Hokm Abadi ME, Bakhti M, Nazemi M, Sedighi S, Mirzadeh Toroghi E. The relationship between personality traits and drug
type among Substance Abuse. J Res Health. 2018;8(6):531-40. doi: 10.29252/jrh.8.6.531.
4. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2021. 2021. https://www.unodc.org/unodc/en/
data-and-analysis/wdr2021.html.
5. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance
use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 2015;10(2):e0116820. doi: 10.1371/journal.pone.0116820.
6. SGI Global. Afghanistan National Drug Use Survey 2015. 2015. https://www.issup.net/knowledge-share/publications/2016-10/afghanistan-national-drug-usesurvey-2015. Accessed January 22, 2020.
7. Kamminga J. States simply do not care: the failure of international securitisation of drug control in Afghanistan.
Int J Drug Policy. 2019;68:3-8. doi: 10.1016/j.drugpo.2019.03.019.
8. U.S. Department of State. Background Note: Afghanistan. 2011. http://www.state.gov/r/pa/ei/bgn/5380.htm. Accessed January 2, 2012.
9. Ventegodt S, Merrick J. Psychoactive drugs and quality of life. ScientificWorldJournal. 2003;3:694-706. doi: 10.1100/
tsw.2003.57.
10. Millson PE, Challacombe L, Villeneuve PJ, Fischer B, Strike CJ, Myers T, et al. Self-perceived health among Canadian
opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health.
2004;95(2):99-103. doi: 10.1007/bf03405775.
11. Copello AG, Templeton L, Velleman R. Family interventions for drug and alcohol misuse: is there a best practice? Curr
Opin Psychiatry. 2006;19(3):271-6. doi: 10.1097/01.yco.0000218597.31184.41.
12. Laudet AB. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract. 2011;6(1):44-55.
13. Karow A, Reimer J, Schäfer I, Krausz M, Haasen C, Verthein U. Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend. 2010;112(3):209-15. doi: 10.1016/j.drugalcdep.2010.06.009.
14. Pasareanu AR, Opsal A, Vederhus JK, Kristensen Ø, Clausen T. Quality of life improved following in-patient substance use disorder treatment. Health Qual Life Outcomes. 2015;13:35. doi: 10.1186/s12955-015-0231-7.
15. Ahmadi A, Rahimi A, Wardak MF, Ahmadi H, Lucero-Prisno DE 3rd. Tobacco harm reduction in Afghanistan: a recipe for
improving smokers’ health. Subst Abuse Treat Prev Policy. 2023;18(1):7. doi: 10.1186/s13011-023-00517-2.
16. Eisenberg MD, McCourt A, Stuart EA, Rutkow L, Tormohlen KN, Fingerhood MI, et al. Studying how state health services
delivery policies can mitigate the effects of disasters on drug addiction treatment and overdose: protocol for a mixedmethods study. PLoS One. 2021;16(12):e0261115. doi: 10.1371/journal.pone.0261115.
17. Shayan NA, Arslan UE, Hooshmand AM, Arshad MZ, Ozcebe H. The Short Form Health Survey (SF-36): translation
and validation study in Afghanistan. East Mediterr Health J. 2020;26(8):899-908. doi: 10.26719/emhj.20.064.
18. United Nations Office on Drugs and Crime (UNODC). Drug Use in Afghanistan: 2009 Survey. Executive Summary.
UNODC; 2009.
19. Rasekh B, Saw YM, Azimi S, Kariya T, Yamamoto E, Hamajima N. Associations of treatment completion against
drug addiction with motivational interviewing and related factors in Afghanistan. Nagoya J Med Sci. 2018;80(3):329-40.
doi: 10.18999/nagjms.80.3.329.
20. Shayan NA, Niazi AU, Moheb H, Mohammadi H, Ahmad Saddiqi KW, Dag O, et al. Epidemiology of drug use in
herat - Afghanistan. Addict Health. 2022;14(2):68-77. doi: 10.22122/ahj.2022.195606.1223.
21. Niazi AU, Shayan NA, Ozgur S, Joya SA, Ozcebe H. Waterpipe smoking among herat university students:
prevalence, attitudes, and associated factors. Addict Health. 2020;12(4):235-43. doi: 10.22122/ahj.v12i4.277.
22. Hafeiz HB. Socio-demographic correlates and pattern of drug abuse in eastern Saudi Arabia. Drug Alcohol Depend.
1995;38(3):255-9. doi: 10.1016/0376-8716(95)90001-x.
23. Mutlu E, Alaei A, Tracy M, Waye K, Cetin MK, Alaei K. Correlates of injection drug use among individuals admitted
to public and private drug treatment facilities in Turkey. Drug Alcohol Depend. 2016;164:71-81. doi: 10.1016/j.
drugalcdep.2016.04.032.
24. Shrestha N, Mehata S, Pradhan PMS, Joshi D, Mishra SR. A nationally representative study on socio-demographic and
geographic correlates, and trends in tobacco use in Nepal. Sci Rep. 2019;9(1):2682. doi: 10.1038/s41598-019-39635-y.
25. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306(6890):1437-40. doi: 10.1136/bmj.306.6890.1437.
26. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med.
1998;26(4):250-8. doi: 10.1177/14034948980260040401.
27. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation
study of the Iranian version. Qual Life Res. 2005;14(3):875-82. doi: 10.1007/s11136-004-1014-5.
28. Neale J. Measuring the health of Scottish drug users. Health Soc Care Community. 2004;12(3):202-11. doi: 10.1111/j.1365-
2524.2004.00489.x.
29. Aghayan S, Amiri M, Chaman R, Khosravi A. Quality of life in methadone maintenance treated patients in Iran. Int J High Risk Behav Addict. 2015;4(4):e22275. doi: 10.5812/ijhrba.22275.
30. Hoseinifar J, Zirak SR, Shaker A, Meamar E, Moharami H, Siedkalan MM. Comparison of quality of life and mental
health of addicts and non- addicts. Procedia Soc Behav Sci. 2011;30:1930-4. doi: 10.1016/j.sbspro.2011.10.375.
31. Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, et al. Canadian normative data for
the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ. 2000;163(3):265-71.
32. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53(1):46-50. doi:
10.1136/jech.53.1.46.
33. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. The Health Institute; 1993.
34. Abadi MH, Shamblen SR, Courser M, Johnson KW, Thompson K, Young L, et al. Gender differences in Afghan drug-abuse
treatment: an assessment of treatment entry characteristics, dropout, and outcomes. Ethn Health. 2015;20(5):453-73. doi:
10.1080/13557858.2014.921898.
35. Cottler LB, Ajinkya S, Goldberger BA, Ghani MA, Martin DM, Hu H, et al. Prevalence of drug and alcohol use in urban
Afghanistan: epidemiological data from the Afghanistan National Urban Drug Use Study (ANUDUS). Lancet Glob Health. 2014;2(10):e592-600. doi: 10.1016/s2214-109x(14)70290-6.
36. Falck RS, Wang J, Carlson RG, Siegal HA. Crack-cocaine use and health status as defined by the SF-36. Addict Behav.
2000;25(4):579-84. doi: 10.1016/s0306-4603(99)00040-4.